The Company, referred to as BCII, was formerly a shell. On December 15, 2021, BCIi completed the acquisition of 100% of the capital stock of NFT Clearing, Inc. pursuant to a Share Exchange Agreement. Additionally, on or about July 17, 2022, BCII purchased 100% of the capital stock of YourInfo.com Co... The Company, referred to as BCII, was formerly a shell. On December 15, 2021, BCIi completed the acquisition of 100% of the capital stock of NFT Clearing, Inc. pursuant to a Share Exchange Agreement. Additionally, on or about July 17, 2022, BCII purchased 100% of the capital stock of YourInfo.com Corp. In connection with its acquisitions of NFT Clearing on December 15, 2021, and YourInfo on July 17, 2022, and that during the period from January 2022 through October 2022, BCII received advances of approximately $520,000 to fund BCII's operations and that of its subsidiaries, including hiring consultants to provide bona fide services and since March 2022 received investments evidenced by software technology designed to enable users to download all the information that any website gathers on them such as Facebook, Google and Amazon, which was previously difficult to access, BCII ceased being a shell company and became a non-shell company effective on August 1, 2022.. YourInfo translates the information for individual users providing the technology they need to gather their data from Web 2.0 sites so that they can market that data for themselves, so as to act as the unique bridge to Web 3.0, NFT Clearing has teamed up with a regulated NFT exchange to allow the trading of the individual's unique key that advertisers will use to view the aforementioned data, which key will be auctioned off on the regulated NFT exchange. 詳細を表示
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader in the development and online marketing of OTC health and wellness products...
Genzyme, Bone Care International Announce Shareholder Approval of Merger Acquisition to Strengthen Genzyme's Growing Renal Business CAMBRIDGE, Mass. and MIDDLETON, Wis., June 30...
Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review CAMBRIDGE, Mass. and MADISON, Wis., June 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and...
Bone Care International Announces Patent Issuance Patent for Stabilized Hydroxyvitamin D2 Products Covers Hectorol(R) (doxercalciferol) MIDDLETON, Wis., June 7 /PRNewswire-FirstCall/ -- Bone...
Medicare Part D Coverage to Include D-Hormones MIDDLETON, Wis., May 18 /PRNewswire-FirstCall/ -- Bone Care International, Inc. (NASDAQ:BCII) announces that the Centers for Medicare and...
Bone Care International Announces Advancement of LR-103 Into Human Patients With Stage 5 Chronic Kidney Disease - New Vitamin D Hormone Replacement Therapy for Chronic Kidney Disease...
Genzyme and Bone Care International Announce Merger Agreement Genzyme to Acquire Bone Care, Adding Complementary Therapy to Renagel; Accelerates Commercial Entry into Earlier Stages of Chronic...
Bone Care International, Inc. Reports Third Quarter FY 2005 Financial Results - Quarterly Hectorol(R) Sales of $22.0 Million, 89% Increase - MIDDLETON, Wis., April 26 /PRNewswire-FirstCall/...
Bone Care International Names Charles W. Bishop, Ph.D., as Executive Vice President and Chief Scientific Officer MIDDLETON, Wis., April 25 /PRNewswire-FirstCall/ -- Bone Care International, Inc...
Bone Care International to Present at Deutsche Bank Health Care Conference MIDDLETON, Wis., April 22 /PRNewswire-FirstCall/ -- Bone Care International, Inc. (NASDAQ:BCII) today announced that...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0009 | 6 | 0.015 | 0.01735 | 0.01085 | 472000 | 0.01330219 | CS |
4 | 0.0032 | 25.1968503937 | 0.0127 | 0.019 | 0.01085 | 212953 | 0.01470164 | CS |
12 | -0.00355 | -18.2519280206 | 0.01945 | 0.020785 | 0.01025 | 108488 | 0.01443628 | CS |
26 | -0.0001 | -0.625 | 0.016 | 0.035 | 0.01025 | 87933 | 0.01772503 | CS |
52 | -0.0081 | -33.75 | 0.024 | 0.0399 | 0.01025 | 68918 | 0.02005105 | CS |
156 | -0.2241 | -93.375 | 0.24 | 0.3 | 0.01025 | 45811 | 0.0653483 | CS |
260 | -0.8841 | -98.2333333333 | 0.9 | 9 | 0.01025 | 75070 | 0.40158813 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約